{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:06:46Z","timestamp":1772168806352,"version":"3.50.1"},"update-to":[{"DOI":"10.12688\/f1000research.110356.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000}}],"reference-count":22,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>The cornerstone of inflammatory bowel disease (IBD) treatment is immunomodulators. IBD patients are at increased risk of intestinal and extraintestinal malignancy. Ustekinumab is a fully humanized monoclonal anti-IL12\/23 antibody with a good safety profile. Malignancies of breast, colon, head and neck, kidney, prostate, thyroid, and non-melanoma skin cancer have been reported among patients who received ustekinumab. We report the case of a 42-year-old Crohn\u2019s patient on long-term treatment with ustekinumab, who developed achromatic malignant melanoma. Crohn\u2019s was diagnosed at the age of 15, with upper and lower gastrointestinal involvement and was initially treated with azathioprine (2mg\/kg for 4 years) and infliximab (5mg\/kg for 6 weeks). Due to ileal obstruction, the patient underwent stricturoplasty and received adalimumab (40mg every other week) for two years. He then discontinued therapy and a year later underwent right hemicolectomy. Adalimumab was reinstituted (40mg every other week) and the patient remained in clinical remission for two years. His overall exposure to adalimumab was four years. Ustekinumab was initiated due to a relapse and after 3 years, an incident of scalp itching led to the diagnosis metastatic achromatic malignant melanoma bearing BRAF V600E mutation. He received targeted therapy with an initial good response. We aim to point out the risk of dermatologic malignancy in IBD patients on long-term immunosuppression and the lifelong and meticulous evaluation that is required.<\/ns4:p>","DOI":"10.12688\/f1000research.110356.2","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T11:50:07Z","timestamp":1696420207000},"page":"424","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Malignant melanoma in a patient with Crohn\u2019s disease treated with ustekinumab"],"prefix":"10.12688","volume":"11","author":[{"given":"Georgios","family":"Axiaris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1488-7533","authenticated-orcid":false,"given":"Alexandros","family":"Ioannou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Papoutsaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonidas","family":"Marinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Liontos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyridon","family":"Michopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evanthia","family":"Zampeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1030-1038","DOI":"10.1053\/j.gastro.2005.12.035","article-title":"Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis.","volume":"130","author":"M Rutter","year":"2006","journal-title":"Gastroenterology."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"526-535","DOI":"10.1136\/gut.48.4.526","article-title":"The risk of colorectal cancer in ulcerative colitis: a meta-analysis.","volume":"48","author":"J Eaden","year":"2001","journal-title":"Gut."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1807-1816.e1","DOI":"10.1053\/j.gastro.2011.01.057","article-title":"Intestinal inflammation and cancer.","volume":"140","author":"T Ullman","year":"2011","journal-title":"Gastroenterology."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1480-1487","DOI":"10.1038\/ajg.2009.760","article-title":"Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies.","volume":"105","author":"N Pedersen","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"136-145","DOI":"10.1159\/000509544","article-title":"Malignancies in Inflammatory Bowel Disease.","volume":"101","author":"T Greuter","year":"2020","journal-title":"Digestion."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1621-1628.e5","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.","volume":"141","author":"L Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"210-218","DOI":"10.1016\/j.cgh.2013.04.033","article-title":"Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis.","volume":"12","author":"S Singh","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2406-2413","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease.","volume":"311","author":"N Nyboe Andersen","year":"2014","journal-title":"JAMA."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"787-794","DOI":"10.1001\/jamadermatol.2020.1300. doi: 10.1001\/jamadermatol.2020.1300","article-title":"Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis.","volume":"156","author":"S Esse","year":"2020 Jul 1","journal-title":"JAMA Dermatol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"321-328","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Review of the safety and efficacy of ustekinumab.","volume":"3","author":"E Scherl","year":"2010 Sep","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"724-732","DOI":"10.1111\/cup.12364","article-title":"Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma.","volume":"41","author":"M Pearlstein","year":"2014","journal-title":"J. Cutan. Pathol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1896-1907","DOI":"10.1093\/rheumatology\/kex434","article-title":"Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.","volume":"57","author":"M Jani","year":"2018 Nov 1","journal-title":"Rheumatology (Oxford)."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3785-3793","DOI":"10.1158\/0008-5472.CAN-06-3134","article-title":"Interleukin-12 deficiency is permissive for angiogenesis in UV radiation-induced skin tumors.","volume":"67","author":"S Meeran","year":"2007 Apr 15","journal-title":"Cancer Res."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"E199-E200","DOI":"10.1002\/ibd.21877","article-title":"Malignant Melanoma During Ustekinumab Therapy of Crohn's Disease.","volume":"18","author":"L Ehmann","year":"1 January 2012","journal-title":"Inflamm. Bowel Dis."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"78-88","DOI":"10.1016\/j.cyto.2016.09.013","article-title":"Do Tumor Necrosis Factor Inhibitors Increase Cancer Risk in Patients With Chronic Immune-Mediated Inflammatory Disorders?.","volume":"101","author":"Y Chen","year":"2018","journal-title":"Cytokine."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"6-15","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy.","volume":"120","author":"P Berraondo","year":"2019 Jan","journal-title":"Br. J. Cancer."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"751-768","DOI":"10.1007\/s40264-019-00797-3","article-title":"Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II\/III Clinical Development Programs.","volume":"42","author":"S Ghosh","year":"2019 Jun","journal-title":"Drug Saf."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1105-1114","DOI":"10.1007\/s40265-017-0765-6","article-title":"Ustekinumab: A Review in Moderate to Severe Crohn's Disease.","volume":"77","author":"Y Lamb","year":"2017 Jul","journal-title":"Drugs."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"57-60","DOI":"10.1111\/j.1440-0960.2011.00853.x","article-title":"The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis.","volume":"53","author":"L Young","year":"2012 Feb","journal-title":"Australas. J. Dermatol."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12522","article-title":"Long-term therapy with ustekinumab for psoriasis in a patient with a history of malignant melanoma.","volume":"30","author":"S Gkalpakiotis","year":"2017 Nov","journal-title":"Dermatol. Ther."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1350-1351","DOI":"10.1002\/ccr3.2225","article-title":"Sequential treatment with secukinumab and ustekinumab in a patient with severe psoriasis and recent history of cerebral malignant melanoma metastasis.","volume":"7","author":"M Ghazanfar","year":"2019","journal-title":"Clin. Case Rep."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2610-2618","DOI":"10.1007\/s11605-021-04913-6","article-title":"Extent of Surgical Resection in Inflammatory Bowel Disease Associated Colorectal Cancer: a Population-Based Study.","volume":"25","author":"J Bogach","year":"2021 Oct","journal-title":"J. Gastrointest. Surg."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/11-424\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/11-424\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/11-424\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T04:30:09Z","timestamp":1697776209000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/11-424\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":22,"URL":"https:\/\/doi.org\/10.12688\/f1000research.110356.2","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.156888.r212109","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.156888.r212109","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,4]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/11-424\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.121953.r148374, Giovanni Marasco, Department of Medical and Surgical Sciences, University of Bologna, Bologna, 05 Sep 2022, version 1, 1 approved, 1 approved with reservations","URL":"https:\/\/f1000research.com\/articles\/11-424\/v1#referee-response-148374","order":0,"name":"referee-response-148374","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.156888.r212109, Sophie Vieujean, University Hospital CHU of Li\u00e8ge, Li\u00e8ge, 20 Oct 2023, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/11-424\/v2#referee-response-212109","order":1,"name":"referee-response-212109","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}